Dosing & Administration

FIRAZYR (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.¹

FIRAZYR is the first prefilled, self-administered, subcutaneous injection to treat acute HAE attacks, that is ready to use as soon as patients recognize the symptoms of an attack¹

• Requires no reconstitution/mixing, no dose calculation, no special handling, no dose titration, and no refrigeration¹
  • FIRAZYR may be stored at room temperature. Store between 36°F and 77°F (2°C and 25°C).
• FIRAZYR is administered over at least 30 seconds into the abdominal area.¹
• Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack, after training by a healthcare professional.¹
• FIRAZYR is available as a 3-mL, prefilled, single-use syringe (30 mg).¹
• If response is inadequate or symptoms recur, additional doses may be administered at intervals of 6 hours or longer.¹
  • No more than 3 doses may be used in a 24-hour period
• FIRAZYR is available in a convenient pack containing 3 cartons¹
  • Single cartons are also available